|
|
Post by notamnkdmillionaire on Oct 28, 2013 18:50:56 GMT -5
|
|
|
|
Post by mdcenter61 on Oct 29, 2013 11:39:53 GMT -5
Lets see....MRK has around 2.9 billion shares, so a 1 for 1 share swap for an outright BO of MNKD would be only around a 12% dilution for them - I'll take that $45 MRK for my $5 MNKD shares, LOL. From a partnership standpoint rather than an outright buyout, Merck does have a pretty good war chest of cash ($13 billion) and available credit! Roll, Joe, lets get it done!
|
|
|
|
Post by mdcenter61 on Oct 29, 2013 11:56:06 GMT -5
One other interesting tie-in is that one of Greenhill's directors served as a director on Merck's board until 2012 (from Greenhill's site):
Steven F. Goldstone, 67, has served on our Board of Directors since July 2004. He currently manages Silver Spring Group, a private investment firm. From 1995 until his retirement in 2000, Mr. Goldstone was chairman and chief executive officer of RJR Nabisco, Inc. (which was subsequently named Nabisco Group Holdings following the reorganization of RJR Nabisco, Inc.). Prior to joining RJR Nabisco, Inc., Mr. Goldstone was a partner at Davis Polk & Wardwell, a law firm in New York City. He is also the non-executive Chairman of ConAgra Foods, Inc. Mr. Goldstone served as a member of the board of directors of Trane, Inc. (f/k/a American Standard Companies, Inc.) from 2002 until 2008 and as a member of the board of directors of Merck & Co. from 2008 until 2012.
|
|
